Genmab — Maj 2021
-
Torsdagens danske avisuddrag med Bitcoin, Salling Group og Rockwool: https://www.proinvestor.com/investornyt/675239/torsdagens-danske-avisuddrag-med-bitcoin-salling-group-og-rockwool
-
Er svagheden i biotekaktier forbigående?
Bryder Novo Nordisk ud af sit kursinterval? Er inflationsfaren reel – eller er det et buzzword? Samt verden ifølge elonmusk
& tsla. Lyt med i afsnit 66 af Investeringspodcasten med PerNordnet
ogHelgeLarsen. https://www.nordnet.dk/blog/afsnit-66-af-investeringspodcasten-om-biotekaktier-og-verden-ifoelge-elon-musk/
. -
Bulder 13.56 tusind tak for info
-
ASCO : Updated phase 1 results of teclistamab - https://meetinglibrary.asco.org/record/195433/abstract
-
ASCO : Updated results of a phase 1, first-in-human study of talquetamab - https://meetinglibrary.asco.org/record/195432/abstract
-
I didn't realise JNJ are also trying Amivantamab subcutaneous WITHOUT hyaluronidase , so just SC administration of a low concentration (50 mg/mL) formulation of amivantamab alone. Let's hope that works well enough. https://meetinglibrary.asco.org/record/201164/abstract
-
any thoughts on Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed? https://meetinglibrary.asco.org/record/196820/abstract
not sure if this is the same sub-group as previously presented? -
Lidt konkurrence til Genmab og Biontech
https://www.fiercebiotech.com/biotech/numab-raises-111m-to-challenge-genmab-biontech-for-emerging-pd-l1-opportunity -
JNJ press release - Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer - https://www.jnj.com/updated-amivantamab-and-lazertinib-combination-data-demonstrate-durable-responses-and-clinical-activity-for-osimertinib-relapsed-patients-with-egfr-mutated-non-small-cell-lung-cancer
-
-
one more then - Biotech
ASCO: Johnson & Johnson's bispecific lung cancer combo shows promise as Tagrisso backup, but the Big Pharma wants more https://www.fiercebiotech.com/biotech/asco-janssen-s-bispecific-lung-cancer-combo-shows-promise-as-tagrisso-back-up-but-big -
ASCO : A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors. https://meetinglibrary.asco.org/record/196008/abstract
-
another maintenance abstract - Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA https://meetinglibrary.asco.org/record/195444/abstract
-
and one more maintenance on the Auriga trial, Dara vs SOC https://meetinglibrary.asco.org/record/201317/abstract
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind